SCHEMBL9944180

SCHEMBL9944180

COc1c(C)cc(C(=O)Nc2ccc(C(C)=O)cc2)cc1Cl

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 4/20 0.65
TAS1R1 Q7RTX1 4/20 0.65
TAS1R2 Q8TE23 3/20 0.65
SMN1; SMN2 Q16637 5/20 0.52
RAB9A P51151 5/20 0.52
NPC1 O15118 3/20 0.52
MAPT P10636 4/20 0.51
TP53 P04637 2/20 0.48
ABCB1 P08183 1/20 0.48
ALDH1A1 P00352 3/20 0.48
GAA P10253 2/20 0.48
KDM4E B2RXH2 2/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
LMNA P02545 2/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
ALOX15 P16050 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9944174 0.90 TAS1R3 (0.59) TAS1R3TAS1R1TAS1R2SMN1; SMN2RAB9A
SCHEMBL9944136 0.90 TAS1R3 (0.65) TAS1R3TAS1R1TAS1R2SMN1; SMN2RAB9A
SCHEMBL9944179 0.87 TAS1R3 (0.52) TAS1R3TAS1R1TAS1R2SMN1; SMN2RAB9A
SCHEMBL9944166 0.86 TAS1R3 (0.51) TAS1R3TAS1R1TAS1R2SMN1; SMN2RAB9A
SCHEMBL9944194 0.86 KMT2A (0.56) TAS1R3TAS1R1TAS1R2SMN1; SMN2RAB9A
SCHEMBL9944206 0.85 TAS1R3 (0.56) TAS1R3TAS1R1TAS1R2SMN1; SMN2RAB9A
SCHEMBL9944199 0.84 TAS1R3 (0.65) TAS1R3TAS1R1TAS1R2SMN1; SMN2RAB9A
SCHEMBL9944203 0.84 TAS1R3 (0.55) TAS1R3TAS1R1TAS1R2SMN1; SMN2RAB9A
SCHEMBL9944138 0.84 TAS1R3 (0.57) TAS1R3TAS1R1TAS1R2SMN1; SMN2RAB9A
SCHEMBL9944196 0.83 TAS1R3 (0.48) TAS1R3TAS1R1TAS1R2SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG TAS1R3 1123/4885TAS1R1 693/4885TAS1R2 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.